Drug Database
DE

dexamethasone (OT502 / IBI10090 / OT 502)

✓ Approved

Ocumension Therapeutics Co., Ltd. · NR3C1 · 类固醇

什么是 dexamethasone?

dexamethasone 是一种类固醇,由Ocumension Therapeutics Co., Ltd.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intraocular Injection。

药物档案

商品名OT502, IBI10090, OT 502
公司Ocumension Therapeutics Co., Ltd.
药物类别类固醇, 小分子
分子靶点NR3C1
给药途径Injectable (Others), Intraocular Injection
状态Approved

作用机制

分子靶点

dexamethasone 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

dexamethasone 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Eye disordersCataract✓ Approved

相关研究文献

PubMedPlant foods for human nutrition (Dordrecht, Netherlands)2026-11-19

Harnessing the Antibacterial Potential of Star Fruit Extract against MRSA: Metabolic Profiling, Molecular Docking, and In Vitro Wound-Healing Effects.

Eraqi Walaa A WA, Mohamed Sally A SA, Hanafi Maha M, Salem Mohamed A MA et al.

Averrhoa carambola L. (star fruit) is recognized for its nutritional value and bioactive constituents. This study investigated its antibacterial and antibiofilm activities against methicillin-resistant Staphylococcus aureus (MRSA) and its potential to promote wound healing. The in vitro antibacterial activity of the extract was evaluated against six MRSA strains by determining the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and time-kill kinetics. The extract exhibited a uniform MIC of 1.95 mg/mL against all tested MRSA strains, while MBC values ranged from 15.6 to 125 mg/mL. Biofilm inhibition was assessed using a crystal violet assay, while transmission electron microscopy and intracellular ion leakage analysis were used to investigate the antibacterial mechanism. The extract significantly inhibited biofilm formation at 0.5 × and 0.25 × MIC, particularly against MS3 and MS15 strains (p ≤ 0.05). The extract induced membrane damage and significant leakage of intracellular phosphate (p = 0.0036) and potassium (p = 0.0001). Its cytocompatibility and wound-healing activity were evaluated using primary human adult dermal fibroblasts (HDFa) and an in vitro scratch assay. The extract showed an EC50 of 2.96 mg/mL without reducing HDFa viability and significantly enhanced wound closure to 70%, compared with 82% for dexamethasone. UPLC-QTOF-MS/MS profiling identified 130 metabolites, with flavonoids representing the predominant class (49 compounds). Molecular docking further predicted favorable binding interactions between selected flavonoids and collagenase, elastase, and lipase. These findings demonstrate the antibacterial, antibiofilm, and in vitro wound-healing potential of star fruit extract against MRSA.

PMID 43052601
阅读全文 →
PubMedEye (London, England)2026-11-19

Incidence and visual outcomes of post-intravitreal injection endophthalmitis: a single-centre analysis of 224,397 injections.

Kayikci Mahmutoglu Gulce G, Simsek Metehan M, Cevik Sadik Gorkem SG, Arici Murat M et al.

Post-injection endophthalmitis (PIE) is a rare, vision-threatening complication of intravitreal injections (IVIs). As IVI volumes rise globally, optimising prevention and management is crucial. This study evaluated PIE incidence, risk factors, microbiology, and outcomes over ten years. A retrospective cohort study of 224,397 IVIs. We analysed demographics, agent type, and preparation (pre-filled syringe [PFS] vs. manual aliquoting). Overall endophthalmitis incidence was 0.029% (n = 65), and 0.026% for anti-VEGFs. PFS-ranibizumab had the lowest incidence (0.014%) and was significantly safer than manually prepared bevacizumab (0.039%; OR: 2.74 [95% CI: 1.36-5.55], p = 0.003); vial-sourced aflibercept (0.027%) was intermediate and not statistically distinguishable from either. Culture positivity was 33.8% (n = 22), predominantly Gram-positive (81.8%), with Staphylococcus epidermidis being the most common (45.5%). In univariate analysis, culture positivity was the sole predictor of worse final visual acuity (VA) (p = 0.030), though limited by small sample sizes. Median VA worsened from 0.61 logMAR at baseline to 2.10 logMAR at presentation, recovering to 1.80 logMAR at final visit (p < 0.001). Among cases initially treated with tap and intravitreal antibiotics (TAI), 60% (21/35) required subsequent vitrectomy (PPV). No baseline clinical parameters predicted TAI success or PPV requirement (all p > 0.05). Dexamethasone implants, with their larger applicator, carried the highest risk. Among anti-VEGFs, PFS ranibizumab demonstrated the most favourable safety profile, with the lowest incidence of PIE. Manual immediate-use bevacizumab aliquoting is a safe, cost-effective alternative in resource-limited settings. In univariate analysis, culture positivity emerged as a negative prognostic factor, though this finding is limited by small sample sizes. Given unpredictable TAI responses, aggressive monitoring and a low PPV threshold are essential.

PMID 43052414
阅读全文 →
PubMedBMC pediatrics2026-11-18

Analysis of adverse reactions to low-dose dexamethasone in bronchopulmonary dysplasia of extremely premature infants: a retrospective study.

Zhuang Genmiao G, Xie Xiaohua X, Chen Jianan J

Bronchopulmonary dysplasia (BPD) represents a prevalent complication among extremely premature infants. Nonetheless, the optimal dosage, treatment duration, and safety profile of dexamethasone require further validation through clinical research. This study investigates the efficacy and safety of low-dose dexamethasone intervention for BPD in extremely preterm infants and establishes an evidence-based foundation for monitoring adverse drug reactions within this population. A retrospective analysis was conducted on 68 cases of extremely preterm infants between March 2016 and January 2024. Among them, 41 cases received dexamethasone treatment (dexamethasone group) while 27 cases did not (control group). The control group received standard respiratory support, nutritional support, anti-infection measures, and other conventional treatments, whereas the dexamethasone group received low-dose dexamethasone in addition to standard care. The primary outcome was a composite endpoint of severe BPD or in-hospital death. Multivariable binary logistic regression was performed adjusting for gestational age, birth weight, and respiratory severity score (RSS). The study compared the extubation success rate, severe BPD incidence, and adverse reactions between the two groups. After adjustment for gestational age, birth weight, and RSS, dexamethasone was associated with lower odds of the composite endpoint of severe BPD or death (adjusted OR = 0.26, 95%CI 0.09-0.55, P = 0.003) and severe BPD among survivors (adjusted OR = 0.27, 95%CI 0.10-0.59, P = 0.005), and higher odds of extubation success (adjusted OR = 2.88, 95%CI 1.20-7.57, P = 0.024). Hyperglycaemia occurred more frequently in the dexamethasone group (41.5% vs. 18.5%, adjusted OR = 2.04, 95%CI 0.82-4.97, P = 0.121), although the difference did not reach statistical significance. In this single-center retrospective cohort, low-dose dexamethasone was associated with lower odds of severe BPD or death and higher odds of extubation success after adjustment for gestational age, birth weight, and respiratory severity. Clinically relevant increases in adverse events, particularly hyperglycaemia, cannot be excluded given the limited sample size. Long-term growth was not assessed. These findings require validation in larger multicenter prospective studies.

PMID 43046014
阅读全文 →
PubMedBritish journal of pharmacology2026-11-18

Model-informed characterisation of the target therapeutic window for dexamethasone by quantitatively balancing foetal lung maturation and neurotoxicity in pregnant rats.

Song Ling L, Zhao Xiaoqi X, Du Ruihu R, Zhang Lei L et al.

Dexamethasone, a first-line treatment for neonatal respiratory distress syndrome (NRDS), promotes foetal lung maturation whilst simultaneously inducing neurotoxicity in offspring. We aimed to define the therapeutic window of dexamethasone for the treatment of NRDS. Pregnant rats were given dexamethasone at 0.1 or 0.4 mg·kg-1 to simulate clinically equivalent prenatal dexamethasone exposure. Half of the rats were anaesthetised, and surfactant proteins A and B in foetal lungs quantified. A pharmacokinetic/pharmacodynamics (PK/PD) model was developed to determine the minimum effective concentration. The remaining rats, delivered naturally, and their offspring underwent open-field testing. Messenger RNA sequencing of the foetal hippocampus was performed, and concentration-toxicity assays were conducted using H19-7/IGF-IR cells. Data were integrated with a maternal-foetal physiologically based pharmacokinetic (PBPK) model to determine the maximum tolerated concentration. A clinical PBPK for dexamethasone in pregnant women was used to simulate a potentially optimal dosing regimen. The PK/PD model adequately characterised dexamethasone-induced foetal lung maturation and indicated a minimal effective concentration of 1.63 ng·ml-1. The offspring of PDE rats exhibited significant behavioural changes. mRNA sequencing analysis suggested that neurotoxicity was mediated via the Wnt pathway and renin-angiotensin system, with BDNF and CMA1 identified as potential biomarkers of neurotoxicity. Cell-based assays suggested a neurotoxic threshold concentration of 17 ng·ml-1. For a therapeutic window of 1.63-17 ng·ml-1, PBPK model simulations indicated that a reduced dose regimen of 2.5 or 3 mg every 8 h for six doses may represent an optimised therapeutic strategy. This model-informed precision dosing strategy provides a rational approach to optimising clinical dexamethasone dosing regimens.

PMID 43046589
阅读全文 →
PubMedJournal of aerosol medicine and pulmonary drug delivery2026-11-18

Inhalable IL-10 as an Aerosolized Therapeutic Approach to Acute Lung Injury in Mice.

Poole Jill A JA, Nelson Amy J AJ, Wyatt Todd A TA, Dudek Steven M SM et al.

Background:Acute lung injury (ALI) is a severe inflammatory condition with substantial morbidity and mortality, with no approved pharmacologic therapies targeting its underlying inflammatory pathways. Prior studies demonstrated that intratracheal interleukin (IL)-10 reduces lipopolysaccharide (LPS)- and organic dust-induced lung and systemic inflammation.Methods:The present study evaluated the aerosol performance and efficacy of nebulized IL-10 against a high-dose LPS-induced ALI model with comparisons to shock-dose dexamethasone (5 mg/kg, intraperitoneal injections). C57BL/6 male mice were challenged with LPS (5 mg/mL) and treated with low- (0.1 mg/mL), mid- (0.5 mg/mL), or high-dose (1 mg/mL) IL-10, or vehicle, all by nose-only aerosol inhalation (15-minute exposure duration), with euthanasia on day 2. Results:Aerosolized IL-10 exhibited a mass median aerodynamic diameter of 1.66 µm (geometric standard deviation 2.04). Pulmonary deposited doses were 5.5-5.7 µg/mouse for LPS and 10.4, 21.3, and 38.4 (ug/kg) for low-, mid-, and high-dose IL-10. LPS-induced weight loss (18.6%) was reduced by high IL-10 (8.4%) and dexamethasone (7.0%), with no significant difference between treatments. Increased lung weights (40.8%) following LPS challenge were significantly reduced by mid- and high-dose IL-10 and dexamethasone. LPS-induced airway total cell and neutrophil counts in bronchoalveolar lavage fluid were not reduced by either treatment. In contrast, IL-10 treatment produced dose-dependent reductions in LPS-induced pro-inflammatory mediators (TNF-α, IL-1β, IL-6, IL-12p70, IFN-γ, KC/CXCL1, MCP-1, and MIP-1α), with beneficial responses at the high IL-10 dose comparable to dexamethasone. Histopathology demonstrated dose-responsive reductions in LPS-induced peribronchovascular mixed cellular lung inflammation, significant at mid- and high IL-10 doses and comparable to dexamethasone.Conclusion:Overall, aerosolized IL-10 demonstrated aerodynamic properties consistent with deep lung penetration and dose-dependent efficacy at ≥21.3 µg/kg, achieving anti-inflammatory effects comparable with dexamethasone in this ALI murine model.

PMID 43046271
阅读全文 →
PubMedTherapeutic advances in hematology2026-11-18

Real-life venous thromboembolism risk scores in multiple myeloma receiving daratumumab, lenalidomide, and dexamethasone.

Liberatore Carmine C, Candeloro Matteo M, Fioritoni Francesca F, Potere Nicola N et al.

Treatment with daratumumab and lenalidomide has improved survival in patients with multiple myeloma (MM), however the risk of venous thromboembolism (VTE) is high. Data on the accuracy of VTE risk scores in MM receiving daratumumab are limited. To assess (i) the prognostic accuracy of available VTE risk scores (IMPEDE-VTE, SAVED, PRISM, and EHR-CAT scores) in non-transplant-eligible MM (NTE-MM) and relapsed/refractory MM (RRMM) consecutively treated with daratumumab, lenalidomide and dexamethasone (Dara-Rd); and (ii) the feasibility and safety of guideline-recommended thromboprophylaxis with low molecular weight heparin for 6 months followed by aspirin (LMWH-ASA). Single-center, retrospective, cohort study. All consecutive MM patients treated with Dara-Rd and concomitant LMWH-ASA thromboprophylaxis between July, 2018 and September, 2023 were evaluated through chart review. Kaplan-Meier method and Concordance-Index (C-index) were used to estimate risk scores' prognostic accuracy. 95 patients (median age 74 years) were included (n= 47 NTE-MM, and n= 48 RRMM). At 12 months from Dara-Rd initiation, 10 (10.4%) patients developed VTE; 4 (4.2%) had bleeding complications, and 2 (2.1%) patients died. Six VTE events (6.2%) occurred within first 6 months from Dara-Rd initiation while on LMWH prophylaxis, whereas 2 VTE (2%) developed in two patients receiving aspirin. The accuracy of IMPEDE-VTE, SAVED, PRISM and EHR-CAT scores was generally poor, with C-Index values ranging from 0.43 (95% confidence intervals [95%CI] 0.30 to 0.56) to 0.53 (95%CI: 0.38 to 0.68). LMWH-ASA prophylaxis was completed by 89.5% of the cohort. In this real-life cohort of MM patients treated with Dara-Rd and guideline-recommended antithrombotic prophylaxis, currently available VTE risk scores demonstrated moderate to poor prognostic accuracy. LMWH-ASA prophylaxis was feasible but associated with residual VTE risk.

PMID 43048015
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多dexamethasone